Core Viewpoint - The Cannabist Company Holdings Inc. has entered into an agreement to sell its Virginia subsidiary, Green Leaf Medical of Virginia, LLC, for a total consideration of $130 million, following a go-shop process that identified a superior acquisition proposal [1][8]. Transaction Details - The sale involves the purchase of all equity interests of Green Leaf Virginia for $130 million, with $117.5 million payable in cash at closing and $12.5 million held in escrow for post-closing adjustments [3]. - The transaction is subject to certain closing conditions, including regulatory approvals, and is expected to close early in 2026 [4]. Financial Implications - The company plans to use a portion of the net proceeds from the transaction to redeem its Senior Secured Notes [5]. Strategic Review - A special committee of independent directors has been formed to explore strategic alternatives, including asset sales and mergers, in light of ongoing operational and financial challenges [9]. Background Information - The Cannabist Company, formerly known as Columbia Care, operates 77 facilities across 12 U.S. jurisdictions, including 61 dispensaries and 16 cultivation and manufacturing facilities [11].

Group 1 - Tilray Brands closed at $12.34, down 4.2%, and has fallen 94% since its IPO in 2018, with trading volume at 66.7 million shares, 514% above its three-month average [1] - The cannabis industry reacted to President Trump's executive order reclassifying marijuana, with the S&P 500 gaining 0.79% and the Nasdaq Composite rising 1.38%, while peers Canopy Growth and Cronos Group fell by 12% and 2% respectively [2] - Following the reclassification of cannabis from Schedule I to Schedule III, Tilray's stock initially rose but ended the day down 4%, indicating a potential "buy the rumor, sell the news" scenario [3][4] Group 2 - The reclassification may not have met investor expectations for broader recreational use, which could have positively impacted Tilray [4] - Despite the recent news, Tilray remains a risky investment as it is barely profitable on an EBITDA basis, although the reclassification should provide some support for the company [4]

impact. Let's bring in Kim Rivery of True Leave. She was at the signing this afternoon.Kim, great to have you with us. >> Thanks so much for having me. How much does this actually help your company and how much of it is symbolic.>> Well, I mean, first of all, the fact that President Trump had the first uh meaningful cannabis policy reform action since cannabis was scheduled back in the 70s. I would say it's a pretty it's a pretty monumental day. Um like you said in the intro, it does two things.It first of ...

With the stroke of his pen on Thursday afternoon, President Donald Trump directed federal officials to reclassify marijuana, loosening restrictions on the drug by signing an executive order in the name of driving medical research. “This reclassification order will make it far easier to conduct marijuana-related medical research, allowing us to study benefits, potential dangers and future treatments,” Trump told reporters in the Oval Office. (1) “It’s going to have a tremendously positive impact.” Must R ...

Cannabis industry stocks rallied this week. Again. It's not that they've been stacking up the gains recently. I'm referring to the on/off news that lights these stocks on fire (pun intended), only to see those hopes go up in...well, you know.I'm Rob Isbitts, founder of Sungarden Investment Publishing. I run the new investing group Sungarden Investors Club, a community dedicated to navigating the modern investment climate with humility, discipline, and a non-traditional approach to income investing. I've bee ...

Schedule III action affirms medical legitimacy and advances a more regulated national cannabis marketTAMPA, Fla., Dec. 18, 2025 (GLOBE NEWSWIRE) -- FLUENT Corp. (CSE: FNT.U) (OTCQB: CNTMF) (“FLUENT” or the “Company”), today applauds the historic federal action directing the rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act, a landmark policy shift that formally recognizes cannabis’s accepted medical use and represents a critical step toward a more rational and regu ...

Core Points - Cannabis has been rescheduled from a Class 1 to a Class 3 substance under the Controlled Substances Act, marking a significant reform in its legal status [1][2] - The new law will enable the IRS to collaborate with legal cannabis businesses, providing them with tax breaks and incentives [1] - The bill aims to enhance cannabis research and redefine hemp to ensure full-spectrum CBD is accessible to patients [2] Industry Impact - The rescheduling is seen as a win for corporate cannabis, but it may pose challenges for smaller craft cannabis operators, potentially disrupting the coexistence of mom-and-pop brands in the industry [5] - Initial reactions in the marijuana stock market were muted, but there is potential for increased trading activity as investors fully digest the news [5] - The cannabis sector may experience a rise in stock prices as the week closes, depending on investor sentiment [5]

Core Viewpoint - The potential rescheduling of marijuana to a Schedule III drug under the Controlled Substances Act could significantly transform the cannabis industry, particularly benefiting Village Farms International, Inc. and its CBDistillery business [1][2]. Group 1: Company Advocacy and Legal Strategy - Village Farms commended President Trump's Executive Order aimed at rescheduling marijuana, which could modernize U.S. cannabis policy and align it with international standards [1][2]. - The company's legal strategy during DEA proceedings was pivotal in advocating for the rescheduling of cannabis, showcasing its commitment to reform and collaboration with policymakers [2]. Group 2: Production and Market Position - Village Farms operates one of the largest cannabis cultivation facilities globally, with 2.2 million square feet of greenhouse assets and 950 acres of farmland in Texas, positioning it well to meet increasing demand for medical cannabis products [2][4]. - The company has a strong foundation in controlled environment agriculture and is leveraging its expertise to expand into cannabinoid-based therapeutic products while maintaining its produce assets [3]. Group 3: International and Domestic Expansion - Internationally, Village Farms is targeting growth opportunities in legal cannabis markets, exporting medical cannabis to countries like Germany, the UK, and Australia, and expanding its export business [5]. - In the U.S., the company plans to enter the THC market using its Texas-based greenhouse assets, which include 2.2 million square feet of existing capacity and additional land for future expansion [6].

The Company confirms it is assessing U.S. licensing pathways for its Canna Cabana retail brand NuLeaf Naturals and FAB CBD evaluating Medicare-aligned product categories CALGARY, AB, Dec. 18, 2025 /PRNewswire/ - High Tide Inc. ("High Tide" or the "Company") (Nasdaq: HITI) (TSXV: HITI) (FSE: 2LYA), the high-impact, retail-forward enterprise built to deliver real-world value across every component of cannabis, today welcomed the Executive Order issued by the White House advancing the rescheduling of cannabis ...

NEW YORK, NY / ACCESS Newswire / December 18, 2025 / The conversation around cannabis reclassification, which was formalized through an executive order signed on Thursday, has focused heavily on policy and capital. Far less attention has been paid to operations. ...